Academic Reading — Test 173

Reading passage

Snakebite envenoming is among the most neglected public health problems facing rural India, yet it rarely attracts the attention or funding directed at more familiar diseases. Each year, venomous snakes inflict a heavy toll on agricultural communities, where people work barefoot in fields, sleep on the ground and live in close proximity to the habitats of the animals that harm them. Although exact figures are difficult to establish, researchers estimate that India records more snakebite deaths than any other country in the world. The majority of these fatalities occur far from hospitals, in villages where medical resources are scarce and where the journey to treatment can take many hours. The danger is concentrated in a small number of species. Four snakes, collectively known as the "Big Four", are responsible for the overwhelming majority of serious cases: the spectacled cobra, the common krait, Russell's viper and the saw-scaled viper. Their venoms attack the body in different ways. The cobra and the krait produce neurotoxins that interfere with the nervous system, gradually paralysing the muscles and, in untreated cases, halting breathing. The two vipers, by contrast, release venom that damages blood vessels and prevents normal clotting, causing severe bleeding and tissue destruction around the wound. Because the effects differ so markedly, accurate identification of the snake responsible would, in principle, allow more precise treatment, but in practice victims and even clinicians frequently cannot say with confidence which species was involved. The standard treatment for envenoming is antivenom, a product whose basic principle has changed little in over a century. To manufacture it, small, carefully measured quantities of venom are injected into large animals, most commonly horses. The animal's immune system responds by generating antibodies against the venom, and these antibodies are later harvested from its blood, purified and processed into a medicine that can neutralise the toxins in a human patient. The Indian product is described as polyvalent, meaning that a single vial is designed to counteract the venoms of all four major species at once. This approach simplifies treatment in emergencies, since the precise identity of the snake need not be known before the medicine is administered. Despite its life-saving potential, antivenom in India suffers from a serious limitation that is only now being widely acknowledged. The venom used to immunise the horses is overwhelmingly sourced from a single region in the south of the country, and for decades it was assumed that a snake of a given species would produce essentially the same venom wherever it lived. Field studies have since shown that this assumption is mistaken. The venom of a Russell's viper in the north can differ substantially in its chemical composition from that of the same species in the south. As a result, antivenom raised against southern venom may prove less effective when used against bites delivered by snakes elsewhere, leaving some patients inadequately protected even when treatment is available. Distribution and storage present further obstacles. Antivenom must be kept cool, and maintaining an unbroken cold chain from the factory to a remote clinic is difficult in a hot climate where electricity supplies are unreliable. Stocks frequently run short during the monsoon months, precisely when bites are most common, because flooding drives snakes and people into closer contact. Treatment also demands trained staff who can recognise the signs of envenoming and manage the allergic reactions that the medicine itself can provoke. Many rural health centres lack such personnel, and frightened patients may instead turn first to traditional healers, losing time that is critical to survival. Public awareness campaigns that teach simple precautions, such as wearing boots and using a torch after dark, can reduce the number of bites, but they reach only a fraction of those at risk. Researchers are now pursuing several routes towards a better solution. Some hope to develop region-specific products tailored to the venoms found in particular parts of the country, while others are working on entirely new technologies that could replace the dependence on horses altogether. Synthetic antibodies and small molecules that block venom toxins directly are among the more promising avenues, though none has yet reached widespread use. In the meantime, the World Health Organization has classified snakebite envenoming as a neglected tropical disease, a designation intended to attract research funding and political commitment. Whether that recognition translates into practical improvement for the farmer bitten at dusk, many kilometres from the nearest functioning clinic, remains an open and pressing question.